

Lab Notebook 2024

Callum Malcolm

Contents

LN Repository	3
Rack 1	3
January 2024	5
February 2024	5
March 2024	5
Monday 24-03-2024	5
MR - CD20 Flow EpiDrug Pretreatment	5
Protocol	5
Results	5
Tuesday 25-03-2024	5
RTX EC50_250324 RBL2 - Seeding	5
Plate seeding protocol:	5
RBL2 RTX DP - Dose 1	6
Dosing Protocol	6
Plate Layout	7
RBL2 RTX DP - Sample Collection Baseline	8
Collection Protocol	8
Thursday 27-03-2024	8
EC50_250325 Collection - RBL2 RTX CDC Baseline	8
Results:	8
RBL2 RTX DP - Dose 1 Collection	8
Collection Protocol	8
Friday 28-03-2024	9
RAMOS-RTXDP SplitSeq: Qubit	9
SS Qubit Results	9
Monday 31-03-2024	9
RAMOS-RTXDP SplitSeq: Library Pooling and Submission	9
RTX EC50_250331 RBL2 - Seeding	9
Plate seeding protocol:	10
April 2025	11
Tuesday 01-04-2024	11
RTX EC50_250401 RBL2 - Seeding	11
Plate seeding protocol:	11

RBL2 RTX DP - Dose 1	12
Dosing Protocol	12
Plate Layout	13

LN Repository

Rack 1

- Location: Tank 2, Rack 1, Row H (Bottom)

Location	Cap ID	Description	Date
1	Grey	Empty - Marker	-
2	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
3	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
4	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
5	C4 DP2	Ramos RTX CDC C4-DP2	-
6	C5 DP2	Ramos RTX CDC C5-DP2	-
7	C1 DP2	Ramos RTX CDC C1-DP2	-
8	R3 DP2	Ramos RTX CDC R3-DP2	-
9	C6 DP2	Ramos RTX CDC C6-DP2	-
10	C3 DP2	Ramos RTX CDC C3-DP2	-
11	C2 DP2	Ramos RTX CDC C2-DP2	-
12	-	-	-
13	-	-	-
14	-	-	-
15	-	-	-
16	-	-	-
17	-	-	-
18	-	-	-
19	-	-	-
20	-	-	-
21	-	-	-
22	-	-	-
23	-	-	-
24	-	-	-
25	-	-	-
26	-	-	-
27	-	-	-
28	-	-	-
29	-	-	-
30	-	-	-
31	Ramos BC 1	Ramos Barcode Pool 1	12/06/2024
32	Ramos BC 1	Ramos Barcode Pool 1	04/01/2023
33	Ramos BC 1	Ramos Barcode Pool 1 *	16/07/2024
34	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
35	Ramos BC 3	Ramos Barcode Pool 3	04/06/2024
36	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
37	Ramos BC 5	Ramos BC Pool 5	12/06/2024
38	Ramos BC 5	Ramos Barcode Pool 5	04/16/2024
39	Ramos BC 6	Ramos Barcode Pool 6	04/16/2024
40	-	-	-
41	-	-	-
42	-	-	-
43	-	-	-
44	-	-	-
45	-	-	-
46	-	-	-
47	-	-	-

Location	Cap ID	Description	Date
48	-	-	-
49	-	-	-
50	-	-	-
51	RBL1	RBL1 PDX	31/07/2023
52	RBL1	RBL1 PDX	31/07/2024
53	RBL1 PDX	RBL1 PDX	31/07/2024
54	BLLW	BLLW PDX Pool	31/07/2024
55	BLLW	BLLW PDX Pool	31/07/2024
56	N4	N4 PDX pool	07/11/2023
57	N4	N4 PDX pool	07/11/2023
58	N2 BC	N2 Barcoded pool	11/05/2023
59	N2 BC 5	N2 barcode pool 5	29/04/2024
60	A20	A20 Cell Pool	13/10/2024
61	A20	A20 Stock	13/10/2024
62	-	-	-
63	-	-	-
64	-	-	-
65	-	-	-
66	-	-	-
67	-	-	-
68	-	-	-
69	-	-	-
70	-	-	-
71	-	-	-
72	-	-	-
73	-	-	-
74	-	-	-
75	-	-	-
76	-	-	-
77	-	-	-
78	-	-	-
79	-	-	-
80	-	-	-
81	-	-	-
82	-	-	-
83	-	-	-
84	-	-	-
85	-	-	-
86	-	-	-
87	-	-	-
88	-	-	-
89	-	-	-
90	-	-	-
91	NA	NA	NA
92	NA	NA	NA
93	NA	NA	NA
94	A20 ME	B-IP-724-1L	-
95	A20 ME	B-IP-723 NM	-
96	A20 ME	B-IP-723-2L	-
97	A20 ME	723-2R	-
98	A20 ME	723-1L	-
99	A20 ME	710 NM - A20 Mouse Experiment	-

Location	Cap ID	Description	Date
100	NA	NA	NA

January 2024

February 2024

March 2024

Monday 24-03-2024

MR - CD20 Flow EpiDrug Pretreatment

Protocol

1. 1×10^6 cells from each treatment group were split into 3 wells of a 96-well plate
2. Plate spun at 300xg 5 min and supernatant discarded
3. Cells were resuspended in FACS Staining buffer
 - 1ul CD20 (BD Cat# 562873) per 250uL
 - 12 uL in 3000uL
4. Plate incubated in the dark for 20min at 4C
5. Plate spun at 300xg 5 min and supernatant discarded
6. Samples were resuspended in 400uL PBS and transferred to FACS tubes

Results

- No clear alteration of CD20 expression due to Epigenetic drug pretreatment

Tuesday 25-03-2024

RTX EC50_250324 RBL2 - Seeding

- Seeded an EC50 experiment comparing the effects of RTX on Baseline RBL2 in the presence of 25% NHS
- Seeded 1 plates with the same RBL2 Baseline population
- Used Rixathon (Catalogue#:)

Plate seeding protocol:

1. Diluted cell suspension to seed 10000 cells/well in 50 μ L amounts

Plate	Cell Line	Cell Count	Required Cell total	Required Volume total	CS cells/mL	Stock Volume (uL)	Media Volume (mL)
Plate 1	RBL2	5.65×10^5	7.00×10^5	3.5	1.61×10^5	1238.9	2.2611

2. Made RTX dilutions and added to respective wells in 25 μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are added in triplicate
 - Drug volumes are being added constitute 1/4 of well volume:

- [RTX working] needs to be 4x [RTX well]
 - 6 wells per condition, 25 μ L per well ~ minimum of 150 μ L per condition needed (recommend 200 μ L)


Dilution ID	Well [RTX] (μ g/mL)	RTX Source	Source Volume (μ L)	Media Volume (μ L)	Working Stock [RTX] (μ g/mL)
RTX 1	20.0	Stock	4.6500000000000004	595.4	79.8
RTX 2	10.0	RTX 1	300	300.0	39.9
RTX 3	5.0	RTX 2	300	300.0	20.0
RTX 4	2.5	RTX 3	300	300.0	10.0
RTX 5	1.2	RTX 4	300	300.0	5.0
RTX 6	0.6	RTX 5	300	300.0	2.5
RTX 7	0.3	RTX 6	300	300.0	1.2
RTX 8	0.2	RTX 7	300	300.0	0.6
RTX 9	0.1	RTX 8	300	600.0	0.3
CNTR	0.0	-	-	1000.0	0.0

3. Added HIAS/NHS to indicated wells

- 25 μ L/well
- Final well volume = 25% Serum (HIAS/NHS)

4. Plate is incubated for 48 hrs at 37C

EC50_250324 CDC Test RBL2



RBL2 RTX DP - Dose 1

- Began RTX CDC In Vitro dosing
- Seeded RBL2 into 2x 6 well plates


Dosing Protocol

1. Count CS and dilute to 2x10⁵ cells in 1 mL
 - If cell count is below either re-culture or add required CS amount, spin down, and resuspend in 1mL
2. Add 1mL of cell suspension containing 2x10⁵ cells to respective wells of 6-well plate


3. Made RTX dilutions and added to respective Rx wells in 500 μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are being added constitute 1/4 of well volume:
 - [RTX working] needs to be 4x [RTX well]
 - 6 wells per RTX dosing, 500 μ L per well ~ minimum of 3000 μ L per condition needed (recommend 3500 μ L)
 - 1.4 uL RTX stock in 3.5mL media
 - 500 μ L media added to Cx wells
4. Added NHS to all wells
 - 500 μ L/well
 - Final well volume = 25% Serum (NHS)
4. Plates incubated for 24 hrs at 37C

Plate Layout

RBL2 RTX DP1 Control 250325



RBL2 RTX DP1 RR-RBL2 250325



RBL2 RTX DP - Sample Collection Baseline

Collection Protocol

1. 1×10^6 cells added to eppendorf tubes
2. Spun down @ max speed @ 4C
3. Supernatant removed
4. Pellets flash frozen
5. Pellets saved at -80C


Thursday 27-03-2024

EC50_250325 Collection - RBL2 RTX CDC Baseline

- Collected plates seeded on 25-03-2025
- EC Plate collection protocol:
 1. Added 20 μ L Cell Titre Blue (CTB) to each conditioned well
 - 20 μ L CTB/100 μ L of conditioned well recommended by manufacturer
 2. Incubated for 2hr at 37C
 3. Read on plate reader according to Cell Titre Blue Protocol

Results:

- HIAS impact on RBL2 CDC similar to RAMOS experiments
- NHS impact on RTX CDC is consistent with previous experiments
 - Cell viability was only reduced to 50%
 - Will repeat with higher doses of RTX (100ug/ml) and more careful cell counting



RBL2 RTX DP - Dose 1 Collection

Collection Protocol

Rx-DP3:

1. Well volume transferred to 15ml Eppendorf
2. Eppendorfs supn down at 200 rcf for 6 min

3. Supernatant discarded and resuspended in 2ml
4. Collected cells added to individual wells of 6-well plates

Friday 28-03-2024

RAMOS-RTXDP SplitSeq: Qubit

- Needed to resubmit library due to low concentration

SS Qubit Results

Sample ID	DNA ng/uL	DNA nM
1	20.4	30.9
2	20.8	31.5
3	6.9	10.4
4	24.4	37.0
5	21.0	31.8
6	12.4	18.8
7	19.4	29.4
8	12.3	18.6

- CRUK-CI Genomics core tends to ask for 30-40uL of 10-20nM Library Pool

Monday 31-03-2024

RAMOS-RTXDP SplitSeq: Library Pooling and Submission

- Library Pooled for submission
- Submission ID: SLX-24264

Library Concentration (ng/μl)	Library Concentration (nM)	Library Volume (μl)	10 mM Tris-HCl, pH 8.5 (μl)	Pooling Volume (μl)
Library 1	30.9	10.3	2.2	4.9
Library 2	31.5	9.9	2.6	5.0
Library 3	10.6	0.0	0.0	11.8
Library 4	37.0	8.5	4.0	5.0
Library 5	31.8	9.8	2.7	5.0
Library 6	18.8	0.0	0.0	6.6
Library 7	29.4	10.6	1.9	5.0
Library 8	18.6	0.0	0.0	6.7

Total Pool Volume	Total Pool Concentration (ng/uL)
50	12.5

RTX EC50_250331 RBL2 - Seeding

- Seeded an EC50 experiment comparing the effects of RTX on Baseline RBL2 in the presence of 25% NHS
- Seeded 1 plates with the RBL2 Baseline population
- Used Rixathon (Catalogue#:)

Plate seeding protocol:

1. Diluted cell suspension to seed 10000 cells/well in 50 μ L amounts


Plate	Cell Line	Cell Count	Required Cell total	Required Volume total	CS cells/mL	Stock Volume (uL)	Media Volume (mL)
Plate 1	RBL2	1.26×10^6	7.00×10^5	3.5	3.60×10^5	555.5	2.9445

2. Made RTX dilutions and added to respective wells in 25 μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are added in triplicate
 - Drug volumes are being added constitute 1/4 of well volume:
 - [RTX working] needs to be 4x [RTX well]
 - 6 wells per condition, 25 μ L per well ~ minimum of 150 μ L per condition needed (recommend 200 μ L)

Dilution ID	Well [RTX] (μ g/mL)	RTX Source	Source Volume (μ L)	Media Volume (μ L)	Working Stock [RTX] (μ g/mL)
RTX 1	100.0	Stock	23.3	576.6	400.1
RTX 2	50.0	RTX 1	299.95	300.0	200.0
RTX 3	25.0	RTX 2	299.95	300.0	100.0
RTX 4	12.5	RTX 3	299.95	300.0	50.0
RTX 5	6.3	RTX 4	299.95	300.0	25.0
RTX 6	3.1	RTX 5	299.95	300.0	12.5
RTX 7	1.6	RTX 6	299.95	300.0	6.3
RTX 8	0.8	RTX 7	299.95	300.0	3.1
RTX 9	0.4	RTX 8	299.95	599.9	1.6
CNTR	0.0	-	-	1000.0	0.0

3. Added HIAS/NHS to indicated wells
 - 25 μ L/well
 - Final well volume = 25% Serum (HIAS/NHS)
4. Plate is incubated for 48 hrs at 37C

EC50_250331 CDC Test RBL2



April 2025

Tuesday 01-04-2024

RTX EC50_250401 RBL2 - Seeding

- Seeded an EC50 experiment comparing the effects of RTX on Baseline RBL2 in the presence of 25% NHS
- Seeded 1 plates with the RBL2 Baseline population
- Used Rixathon (Catalogue#:)

Plate seeding protocol:

1. Diluted cell suspension to seed 10000 cells/well in 50 μ L amounts

Plate	Cell Line	Cell Count	Required Cell total	Required Volume total	CS cells/mL	Stock Volume (uL)	Media Volume (mL)
Plate 1	RBL2	9.70×10^5	7.00×10^5	3.5	2.77×10^5	721.6	2.7784

2. Made RTX dilutions and added to respective wells in 25 μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are added in triplicate
 - Drug volumes are being added constitute 1/4 of well volume:
 - [RTX working] needs to be 4x [RTX well]
 - 6 wells per condition, 25 μ L per well ~ minimum of 150 μ L per condition needed (recommend 200 μ L)


Dilution ID	Well [RTX] ($\mu\text{g/mL}$)	RTX Source	Source Volume (μL)	Media Volume (μL)	Working Stock [RTX] ($\mu\text{g/mL}$)
RTX 1	100.0	Stock	23.3	576.6	400.1
RTX 2	50.0	RTX 1	299.95	300.0	200.0
RTX 3	25.0	RTX 2	299.95	300.0	100.0
RTX 4	12.5	RTX 3	299.95	300.0	50.0
RTX 5	6.3	RTX 4	299.95	300.0	25.0
RTX 6	3.1	RTX 5	299.95	300.0	12.5
RTX 7	1.6	RTX 6	299.95	300.0	6.3
RTX 8	0.8	RTX 7	299.95	300.0	3.1
RTX 9	0.4	RTX 8	299.95	599.9	1.6
CNTR	0.0	-	-	1000.0	0.0

3. Added HIAS/NHS to indicated wells

- $25\mu\text{L}/\text{well}$
- Final well volume = 25% Serum (HIAS/NHS)

4. Plate is incubated for 48 hrs at 37°C

EC50_250331 CDC Test RBL2



RBL2 RTX DP - Dose 1

- Restarted RTX CDC In Vitro dosing
- Concerns with initial seeding/dosing
 - RBL2 appear to be more resistant to RTX dosing
 - Plan is to start with $25\mu\text{g/mL}$ RTX
 - $25 \rightarrow 50 \rightarrow 100 \rightarrow 200$
- Seeded RBL2 into 2x 6 well plates


Dosing Protocol

- Count CS and dilute to 5×10^5 cells in 1 mL
 - If cell count is below either re-culture or add required CS amount, spin down, and resuspend in 1mL
- Add 1mL of cell suspension containing 2×10^5 cells to respective wells of 6-well plate

3. Made RTX dilutions and added to respective Rx wells in 500 μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are being added constitute 1/4 of well volume:
 - [RTX working] needs to be 4x [RTX well]
 - 6 wells per RTX dosing, 500 μ L per well ~ minimum of 3000 μ L per condition needed (recommend 3500 μ L)
 - 1.4 uL RTX stock in 3.5mL media
 - 500 μ L media added to Cx wells
4. Added NHS to all wells
 - 500 μ L/well
 - Final well volume = 25% Serum (NHS)
4. Plates incubated for 24 hrs at 37C

Plate Layout

RBL2 RTX DP1 Control 250325



RBL2 RTX DP1 RR-RBL2 250325

